Physician profile
Geeta K Patel
NPI 1982925186
$575,437.93
in general payments reported to CMS, 2019-2025
51 companies · $241K in 2025
The $241K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $4,506 · 2021: $8,618 · 2022: $10K · 2023: $145K · 2024: $154K · 2025: $241K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $363K · Consulting Fee: $85K · Travel and Lodging: $42K · Food and Beverage: $34K · Honoraria: $15K · Education: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $362,526.65 |
| Consulting Fee | $85,339.19 |
| Travel and Lodging | $41,973.99 |
| Food and Beverage | $33,966.77 |
| Honoraria | $15,260.08 |
| Education | $903.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $150,907.37 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $101,662.61 | 2019-2025 | Aklief, Epsolay, Oracea |
| Ucb, INC. | $79,696.21 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $60,218.37 | 2019-2025 | |
| Leo Pharma INC. | $43,555.72 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Amgen INC. | $25,733.71 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $18,100.79 | 2019-2025 | |
| Organon LLC | $16,877.93 | 2025 | Vtama |
| Abbvie INC. | $12,224.97 | 2019-2025 | |
| Janssen Biotech, INC. | $11,182.13 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Arcutis Biotherapeutics, INC. | $10,319.58 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $8,361.06 | 2019-2025 | Siliq, Duobrii, Targretin |
| Regeneron Healthcare Solutions, INC. | $7,277.18 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $6,027.39 | 2019-2025 | Ebglyss, Taltz |
| Biofrontera INC. | $4,377.95 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geeta Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.